Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Pharmacotherapy for obesity - do the benefits outweigh the risks?

Article Abstract:

The benefits of fenfluramine and its derivatives probably outweigh their side effects. One side effect recently discovered was pulmonary hypertension, a condition characterized by high blood pressure in the lungs. Researchers found that almost one-third of 95 people with pulmonary hypertension had been taking fenfluramine. This translates to a risk 23 times greater than in people who don't use the diet pill. However, obesity has serious health consequences and drug therapy would save an estimated 280 lives for every 1 million persons treated. Fenfluramine would cause an estimated 14 deaths for every 1 million persons treated.

Author: Manson, Joann E., Faich, Gerald A.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1996
Editorial, Pulmonary hypertension

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs

Article Abstract:

The diet pills fenfluramine, dexfenfluramine and/or phentermine may increase the risk of heart valve insufficiency. This occurs when the valves do not close properly. Researchers analyzed the rate of heart valve insufficiency in 233 obese patients who had taken one or a combination of these pills and in 233 people who had not. Compared to those who did not take the pills, the risk of heart valve insufficiency was 12 times higher in obese people who took dexfenfluramine, 24 times higher in those who took dexfenfluramine and phentermine and 26 times higher in those who took fenfluramine and phentermine.

Author: Asinger, Richard W., Herzog, Charles A., Khan, Mehmood A., St. Peter, John V., Hartley, Guilford G., Madlon-Kay, Richard, Dick, Candace D., Vessey, John T.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1998
Phentermine

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation

Article Abstract:

The diet pills fenfluramine and dexfenfluramine appear to increase the risk of heart valve insufficiency. This condition occurs when the valves do not close properly. Researchers analyzed the rate of heart valve insufficiency over a five-year period in approximately 20,000 obese people, half of whom were taking one of these two drugs or another diet pill called phentermine. Within five years, there were 11 cases of heart valve insufficiency in the people taking diet pills, but none in those who were not. The aortic valve was most often affected.

Author: Jick, Hershel, Jick, Susan S., Meier, Christoph, Vasilakis, Catherine, Weinrauch, Larry A., Derby, Laura E.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1998

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Complications and side effects, Risk factors, Drug therapy, Obesity, Fenfluramine, Dexfenfluramine, Heart valve diseases
Similar abstracts:
  • Abstracts: Teaching others new skills can aid your own learning. Reviewing the effectiveness of tympanic thermometers
  • Abstracts: Farm safety finds a home in the heartland. Safety success stories. Even safety follows the leader
  • Abstracts: Informed consent for genetic research on stored tissue samples. Informed consent for population-based research involving genetics. (Health Law and Ethics)
  • Abstracts: Osteoarthritis of the hip and osteoporosis of the proximal femur. Does location of vertebral deformity within the spine influence back pain and disability?
  • Abstracts: Finasteride to prevent morbidity from benign prostatic hyperplasia. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.